FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packageus.nlm.vsac
Resource TypeValueSet
IdValueSet-2.16.840.1.113883.3.1444.3.135.json
FHIR VersionR4
Sourcehttps://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.1444.3.135/expansion
URLhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135
Version20210306
Statusactive
Date2021-03-06T01:00:16-05:00
NameDolasetronOral
TitleDolasetron Oral
Realmus
Authorityhl7
Purpose(Clinical Focus: The purpose of this value set is to represent concepts of medication Dolasetron.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Dolasetron; generic; prescribable; oral.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)

Resources that use this resource

ValueSet
2.16.840.1.113762.1.4.1116.604Serotonin Receptor Antagonist
2.16.840.1.113883.3.1444.5.245Antiemetic Agent

Resources that this resource uses

CodeSystem
rxnormRxNorm

Narrative

No narrative content found in resource


Source1

{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113883.3.1444.3.135",
  "meta": {
    "versionId": "6",
    "lastUpdated": "2023-12-21T17:43:03.000-05:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail": {
        "name": "American Society of Clinical Oncology Author"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate": "2025-04-08"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2021-03-06"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113883.3.1444.3.135"
    }
  ],
  "version": "20210306",
  "name": "DolasetronOral",
  "title": "Dolasetron Oral",
  "status": "active",
  "experimental": false,
  "date": "2021-03-06T01:00:16-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US"
        }
      ]
    }
  ],
  "purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication Dolasetron.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Dolasetron; generic; prescribable; oral.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept": [
          {
            "code": "310006",
            "display": "dolasetron 100 MG Oral Tablet"
          },
          {
            "code": "310007",
            "display": "dolasetron 50 MG Oral Tablet"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:55274ad5-1527-447a-bf06-2a9ec6e4d7c2",
    "timestamp": "2025-05-23T21:52:52-04:00",
    "total": 2,
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "310006",
        "display": "dolasetron 100 MG Oral Tablet"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "310007",
        "display": "dolasetron 50 MG Oral Tablet"
      }
    ]
  }
}